Literature DB >> 23669782

Canaglifozin (Invokana) for type 2 diabetes.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669782

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN: 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  4 in total

1.  Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.

Authors:  Ting Yang; Min Lu; Lingyue Ma; Ying Zhou; Yimin Cui
Journal:  Eur J Clin Pharmacol       Date:  2015-08-19       Impact factor: 2.953

Review 2.  Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement.

Authors:  Sanjay Kalra; A H Aamir; Abbas Raza; A K Das; A K Azad Khan; Dina Shrestha; Md Faisal Qureshi; Md Faruque Pathan; Fatema Jawad; Jyoti Bhattarai; Nikhil Tandon; Noel Somasundaram; Prasad Katulanda; Rakesh Sahay; Sanjib Dhungel; Sarita Bajaj; Subhankar Chowdhury; Sujoy Ghosh; S V Madhu; Tofail Ahmed; Uditha Bulughapitiya
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

3.  Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

Authors:  Nobuya Inagaki; Kazuoki Kondo; Toru Yoshinari; Hideki Kuki
Journal:  J Diabetes Investig       Date:  2014-08-25       Impact factor: 4.232

4.  Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.

Authors:  William T Cefalu; John B Buse; Stefano Del Prato; Philip D Home; Derek LeRoith; Michael A Nauck; Itamar Raz; Julio Rosenstock; Matthew C Riddle
Journal:  Diabetes Care       Date:  2014-09       Impact factor: 19.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.